|
1
|
Leon-Ferre RA, Hieken TJ and Boughey JC:
The landmark series: Neoadjuvant chemotherapy for triple-negative
and HER2-positive breast cancer. Ann Surg Oncol. 28:2111–2119.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG), . Early Breast Cancer Trialists'
Collaborative Group (EBCTCG): Long-term outcomes for neoadjuvant
versus adjuvant chemotherapy in early breast cancer: Meta-analysis
of individual patient data from ten randomised trials. Lancet
Oncol. 19:27–39. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
King TA and Morrow M: Surgical issues in
patients with breast cancer receiving neoadjuvant chemotherapy. Nat
Rev Clin Oncol. 12:335–343. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Provenzano E: Neoadjuvant chemotherapy for
breast cancer: Moving beyond pathological complete response in the
molecular age. Acta Med Acad. 50:88–109. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
von Minckwitz G, Untch M, Blohmer JU,
Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich
J, Huober J, et al: Definition and impact of pathologic complete
response on prognosis after neoadjuvant chemotherapy in various
intrinsic breast cancer subtypes. J Clin Oncol. 30:1796–1804. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Houssami N, Macaskill P, von Minckwitz G,
Marinovich ML and Mamounas E: Meta-analysis of the association of
breast cancer subtype and pathologic complete response to
neoadjuvant chemotherapy. Eur J Cancer. 48:3342–3354. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Swain SM, Tang G, Lucas PC, Robidoux A,
Goerlitz D, Harris BT, Bandos H, Geyer CE Jr, Rastogi P, Mamounas
EP and Wolmark N: Pathologic complete response and outcomes by
intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of
chemotherapy with trastuzumab, lapatinib, or the combination.
Breast Cancer Res Treat. 178:389–399. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
von Minckwitz G, Huang CS, Mano MS, Loibl
S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A,
Redondo A, et al: Trastuzumab emtansine for residual invasive
HER2-positive breast cancer. N Engl J Med. 380:617–628. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES,
Yokota I, Kuroi K, Im SA, Park BW, Kim SB, et al: Adjuvant
capecitabine for breast cancer after preoperative chemotherapy. N
Engl J Med. 376:2147–2159. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ding YC, Steele L, Warden C, Wilczynski S,
Mortimer J, Yuan Y and Neuhausen SL: Molecular subtypes of
triple-negative breast cancer in women of different race and
ethnicity. Oncotarget. 10:198–208. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huo D, Hu H, Rhie SK, Gamazon ER,
Cherniack AD, Liu J, Yoshimatsu TF, Pitt JJ, Hoadley KA, Troester
M, et al: Comparison of breast cancer molecular features and
survival by african and european ancestry in the cancer genome
atlas. JAMA Oncology. 3:1654–1662. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Keenan T, Moy B, Mroz EA, Ross K,
Niemierko A, Rocco JW, Isakoff S, Ellisen LW and Bardia A:
Comparison of the genomic landscape between primary breast cancer
in African American versus white women and the association of
racial differences with tumor recurrence. J Clin Oncol.
33:3621–3627. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rajagopal PS, Reid S, Fan R, Venton L,
Weidner A, Roberson ML, Vadaparampil S, Wang X, Yoder S, Rosa M, et
al: Population-specific patterns in assessing molecular subtypes of
young black females with triple-negative breast cancer. NPJ Breast
Cancer. 11:282025. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Martini R, Newman L and Davis M: Breast
cancer disparities in outcomes; unmasking biological determinants
associated with racial and genetic diversity. Clin Exp Metastasis.
39:7–14. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Global Cancer Observatory, . Cancer Today.
Lyon, France: International Agency for Research on Cancer.
Available from. https://gco.iarc.who.int/media/globocan/factsheets/populations/384-cote-divoire-fact-sheetMay
2–2024
|
|
16
|
Joko-Fru WY, Miranda-Filho A,
Soerjomataram I, Egue M, Akele-Akpo MT, N'da G, Assefa M, Buziba N,
Korir A, Kamate B, et al: Breast cancer survival in sub-Saharan
Africa by age, stage at diagnosis and human development index: A
population-based registry study. Int J Cancer. 146:1208–1218. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Teichgraeber DC, Guirguis MS and Whitman
GJ: Breast cancer staging: Updates in the AJCC cancer staging
manual, 8th edition, and current challenges for radiologists, from
the AJR special series on cancer staging. AJR Am J Roentgenol.
217:278–290. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Farrukh N, Bano R, Naqvi SRQ and Latif H:
Assessment of pathological complete response in patients with
breast cancer receiving neoadjuvant systemic therapy. J Coll
Physicians Surg Pak. 32:746–750. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cirier J, Body G, Jourdan ML, Bédouet L,
Fleurier C, Pilloy J, Arbion F and Ouldamer L: Impact de la réponse
histologique complète à la chimiothérapie néo-adjuvante pour cancer
du sein selon le sous-type moléculaire. Gynécol Obstétrique
Fertilité Sénologie. 45:535–544. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cortazar P, Zhang L, Untch ML, Bedouet L,
Fleurier C, Pilloy J, Arbion F and Ouldamer L: Pathological
complete response and Long-term clinical benefit in breast cancer:
The CTNeoBC pooled analysis. Lancet. 384:164–172. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Müller C, Schmidt G, Juhasz-Böss I, Jung
L, Huwer S, Solomayer EF and Juhasz-Böss S: Influences on
pathologic complete response in breast cancer patients after
neoadjuvant chemotherapy. Arch Gynecol Obstet. 304:1065–1071. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Foldi J, Mougalian S, Silber A, Lannin D,
Killelea B, Chagpar A, Horowitz N, Frederick C, Rispoli L, Burrello
T, et al: Single-arm, neoadjuvant, phase II trial of pertuzumab and
trastuzumab administered concomitantly with weekly paclitaxel
followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC)
for stage I–III HER2-positive breast cancer. Breast Cancer Res
Treat. 169:333–340. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gianni L, Pienkowski T, Im YH, Roman L,
Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J,
Im SA, et al: Efficacy and safety of neoadjuvant pertuzumab and
trastuzumab in women with locally advanced, inflammatory, or early
HER2-positive breast cancer (NeoSphere): A randomised multicentre,
open-label, phase 2 trial. Lancet Oncol. 13:25–32. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Untch M, Rezai M, Loibl S, Fasching PA,
Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B,
et al: Neoadjuvant treatment with trastuzumab in HER2-positive
breast cancer: results from the GeparQuattro study. J Clin Oncol.
28:2024–2031. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sharma P, Connolly RM, Roussos Torres ET
and Thompson A: Best foot forward: Neoadjuvant systemic therapy as
standard of care in triple-negative and HER2-positive breast
cancer. Am Soc Clin Oncol Educ Book. 40:1–16. 2020. View Article : Google Scholar
|
|
26
|
Boughey JC, Ballman KV, McCall LM,
Mittendorf EA, Symmans WF, Julian TB, Byrd D and Hunt KK: Tumor
biology and response to chemotherapy impact breast cancer-specific
survival in node-positive breast cancer patients treated with
neoadjuvant chemotherapy: Long-term follow-up from ACOSOG Z1071
(Alliance). Ann Surg. 266:667–676. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hieken TJ, Murphy BL, Boughey JC, Degnim
AC, Glazebrook KN and Hoskin TL: Influence of biologic subtype of
inflammatory breast cancer on response to neoadjuvant therapy and
cancer outcomes. Clin Breast Cancer. 18:e501–e506. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Prat A, Fan C, Fernández A, Hoadley KA,
Martinello R, Vidal M, Viladot M, Pineda E, Arance A, Muñoz M, et
al: Response and survival of breast cancer intrinsic subtypes
following multi-agent neoadjuvant chemotherapy. BMC Med.
13:3032015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rouzier R, Perou CM, Symmans WF, Ibrahim
N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P,
et al: Breast cancer molecular subtypes respond differently to
preoperative chemotherapy. Clin Cancer Res. 11:5678–5685. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hadgu E, Seifu D, Tigneh W, Bokretsion Y,
Bekele A, Abebe M, Sollie T, Merajver SD, Karlsson C and Karlsson
MG: Breast cancer in Ethiopia: Evidence for geographic difference
in the distribution of molecular subtypes in Africa. BMC Womens
Health. 18:402018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Brandão M, Guisseve A, Bata G, Alberto M,
Ferro J, Garcia C, Zaqueu C, Lorenzoni C, Leitão D, Come J, et al:
Breast cancer subtypes: implications for the treatment and survival
of patients in Africa-a prospective cohort study from Mozambique.
ESMO Open. 5:e0008292020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Adeniji AA, Dawodu OO, Habeebu MY, Oyekan
AO, Bashir MA, Martin MG, Keshinro SO and Fagbenro GT: Distribution
of breast cancer subtypes among nigerian women and correlation to
the risk factors and clinicopathological characteristics. World J
Oncol. 11:165–172. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Seshie B, Adu-Aryee NA, Dedey F,
Calys-Tagoe B and Clegg-Lamptey JN: A retrospective analysis of
breast cancer subtype based on ER/PR and HER2 status in Ghanaian
patients at the Korle Bu Teaching Hospital, Ghana. BMC Clin Pathol.
15:142015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lehmann BD, Jovanović B, Chen X, Estrada
MV, Johnson KN, Shyr Y, Moses HL, Sanders ME and Pietenpol JA:
Refinement of triple-negative breast cancer molecular subtypes:
Implications for neoadjuvant chemotherapy selection. PLoS One.
11:e01573682016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen XS, Wu JY, Huang O, Chen CM, Wu J, Lu
JS, Shao ZM, Shen ZZ and Shen KW: Molecular subtype can predict the
response and outcome of Chinese locally advanced breast cancer
patients treated with preoperative therapy. Oncol Rep.
23:1213–1220. 2010.PubMed/NCBI
|
|
36
|
Jiagge E, Jibril AS, Chitale D,
Bensenhaver JM, Awuah B, Hoenerhoff M, Adjei E, Bekele M, Abebe E,
Nathanson SD, et al: Comparative analysis of breast cancer
phenotypes in African American, White American, and West versus
east African patients: Correlation between African ancestry and
triple-negative breast cancer. Ann Surg Oncol. 23:3843–3849. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Davis M, Tripathi S, Hughley R, He Q, Bae
S, Karanam B, Martini R, Newman L, Colomb W, Grizzle W and Yates C:
AR negative triple negative or ‘quadruple negative’ breast cancers
in African American women have an enriched basal and immune
signature. PLoS One. 13:e01969092018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Saini G, Bhattarai S, Gogineni K and Aneja
R: Quadruple-negative breast cancer: An uneven playing field. JCO
Glob Oncol. 6:233–237. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bhattarai S, Klimov S, Mittal K,
Krishnamurti U, Li XB, Oprea-Ilies G, Wetherilt CS, Riaz A,
Aleskandarany MA, Green AR, et al: Prognostic role of androgen
receptor in triple negative breast cancer: A Multi-institutional
study. Cancers (Basel). 11:9952019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Asano Y, Kashiwagi S, Goto W, Tanaka S,
Morisaki T, Takashima T, Noda S, Onoda N, Ohsawa M, Hirakawa K and
Ohira M: expression and clinical significance of androgen receptor
in Triple-negative breast cancer. Cancers (Basel). 9:42017.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Thike AA, Yong-Zheng Chong L, Cheok PY, Li
HH, Wai-Cheong Yip G, Huat Bay B, Tse GM, Iqbal J and Tan PH: Loss
of androgen receptor expression predicts early recurrence in
triple-negative and basal-like breast cancer. Mod Pathol.
27:352–360. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Goorts B, van Nijnatten TJA, de Munck L,
Moossdorff M, Heuts EM, de Boer M, Lobbes MB and Smidt ML: Clinical
tumor stage is the most important predictor of pathological
complete response rate after neoadjuvant chemotherapy in breast
cancer patients. Breast Cancer Res Treat. 163:83–91. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Spring LM, Fell G, Arfe A, Sharma C,
Greenup R, Reynolds KL, Smith BL, Alexander B, Moy B, Isakoff SJ,
et al: Pathologic complete response after neoadjuvant chemotherapy
and impact on breast cancer recurrence and survival: A
comprehensive Meta-analysis. Clin Cancer Res. 26:2838–2848. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Villacampa G, Navarro V, Matikas A,
Ribeiro JM, Schettini F, Tolosa P, Martínez-Sáez O, Sánchez-Bayona
R, Ferrero-Cafiero JM, Salvador F, et al: Neoadjuvant immune
checkpoint inhibitors plus chemotherapy in early breast cancer: A
systematic review and Meta-analysis. JAMA Oncol. 10:1331–1341.
2024. View Article : Google Scholar : PubMed/NCBI
|
